Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2020 - 2026)
Quantum Biopharma (QNTM) reported Income from Non-Controlling Interests of $13.8 million for Q1 2026, up 57.37% on a YoY basis from $8.7 million in Q1 2025, and up 127.39% sequentially from -$50.2 million in Q4 2025.
Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 7 years of Income from Non-Controlling Interests data on file, last reported at $13.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 57.37% year-over-year to $13.8 million; the trailing twelve-month figure through Mar 2026 stood at -$41.5 million (down 1150.97% YoY), and the FY2025 full-year result was -$27.0 million, down 80.73% from the prior year.
- Income from Non-Controlling Interests climbed to $13.8 million in Q1 2026, from -$50.2 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $13.8 million in Q1 2026 to a low of -$50.2 million in Q4 2025.
- A 5-year average of -$4.8 million and a median of -$2.1 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests soared 5726.7% in 2024 and plunged 820.24% in 2025, its largest moves.
- Tracing QNTM's Income from Non-Controlling Interests over 5 years: stood at $5.9 million in 2022, then tumbled by 407.51% to -$18.2 million in 2023, then surged by 69.95% to -$5.5 million in 2024, then sank by 820.24% to -$50.2 million in 2025, then jumped by 127.39% to $13.8 million in 2026.
- Business Quant data shows QNTM's Income from Non-Controlling Interests at $13.8 million in Q1 2026, -$50.2 million in Q4 2025, and $4.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - | 13.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.75 Mn |
| Dec 31, 2025 | -50.21 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | -9.77 Mn |
| Mar 31, 2025 | 8.74 Mn |
| Dec 31, 2024 | -5.46 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Dec 31, 2023 | -18.16 Mn |
| Sep 30, 2023 | -71,362.00 |
| Mar 31, 2023 | -9.96 Mn |
| Mar 31, 2022 | 5.91 Mn |
| Jun 30, 2021 | -13.21 Mn |
| Mar 31, 2021 | 9.94 Mn |
| Jun 30, 2020 | -3.24 Mn |
| Mar 31, 2020 | -6.98 Mn |